İ. Doğan Et Al. , "Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine," European Journal of Breast Health , vol.19, no.2, pp.128-133, 2023
Doğan, İ. Et Al. 2023. Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine. European Journal of Breast Health , vol.19, no.2 , 128-133.
Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & AYDINER, A., (2023). Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine. European Journal of Breast Health , vol.19, no.2, 128-133.
Doğan, İzzet Et Al. "Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine," European Journal of Breast Health , vol.19, no.2, 128-133, 2023
Doğan, İzzet Et Al. "Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine." European Journal of Breast Health , vol.19, no.2, pp.128-133, 2023
Doğan, İ. Et Al. (2023) . "Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine." European Journal of Breast Health , vol.19, no.2, pp.128-133.
@article{article, author={İzzet Doğan Et Al. }, title={Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine}, journal={European Journal of Breast Health}, year=2023, pages={128-133} }